INCOVACC (BBV-154) has received Central Drugs Standard Control Organisation (CDSCO) approval under restricted use in an emergency situation for ages 18 and above for heterologous booster doses.
INCOVACC is an intranasal vaccine for Corona Virus (COVID-19) that is prepared by Bharat Biotech International Limited (BBIL). It is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion stabilized spike protein.
It is the first intranasal vaccine to receive both primary series and heterologous booster approval.
The nasal delivery system has been designed and developed to be cost-effective in low- and middle-income countries.
INCOVACC has the double benefit of enabling faster development of variant-specific vaccines and easy nasal delivery that enables mass immunisation to protect from emerging variants of concern.
INCOVACC was developed in partnership with Washington University St. Louis, which had designed and developed the recombinant adenoviral vectored constructs and evaluated them in preclinical studies for efficacy.